Adiponectin and Cognitive Decline

Int J Mol Sci. 2020 Mar 16;21(6):2010. doi: 10.3390/ijms21062010.

Abstract

Adiponectin (ADPN) is a plasma protein secreted by adipose tissue showing pleiotropic effects with anti-diabetic, anti-atherogenic, and anti-inflammatory properties. Initially, it was thought that the main role was only the metabolism control. Later, ADPN receptors were also found in the central nervous system (CNS). In fact, the receptors AdipoR1 and AdipoR2 are expressed in various areas of the brain, including the hypothalamus, hippocampus, and cortex. While AdipoR1 regulates insulin sensitivity through the activation of the AMP-activated protein kinase (AMPK) pathway, AdipoR2 stimulates the neural plasticity through the activation of the peroxisome proliferator-activated receptor alpha (PPARα) pathway that inhibits inflammation and oxidative stress. Overall, based on its central and peripheral actions, ADPN appears to have neuroprotective effects by reducing inflammatory markers, such as C-reactive protein (PCR), interleukin 6 (IL6), and Tumor Necrosis Factor a (TNFa). Conversely, high levels of inflammatory cascade factors appear to inhibit the production of ADPN, suggesting bidirectional modulation. In addition, ADPN appears to have insulin-sensitizing action. It is known that a reduction in insulin signaling is associated with cognitive impairment. Based on this, it is of great interest to investigate the mechanism of restoration of the insulin signal in the brain as an action of ADPN, because it is useful for testing a possible pharmacological treatment for the improvement of cognitive decline. Anyway, if ADPN regulates neuronal functioning and cognitive performances by the glycemic metabolic system remains poorly explored. Moreover, although the mechanism is still unclear, women compared to men have a doubled risk of developing cognitive decline. Several studies have also supported that during the menopausal transition, the estrogen reduction can adversely affect the brain, in particular, verbal memory and verbal fluency. During the postmenopausal period, in obese and insulin-resistant individuals, ADPN serum levels are significantly reduced. Our recent study has evaluated the relationship between plasma ADPN levels and cognitive performances in menopausal women. Thus, the aim of this review is to summarize both the mechanisms and the effects of ADPN in the central nervous system and the relationship between plasma ADPN levels and cognitive performances, also in menopausal women.

Keywords: MCI; adiponectin; cognitive function; dementia.

Publication types

  • Review

MeSH terms

  • AMP-Activated Protein Kinases / metabolism
  • Adiponectin / blood
  • Adiponectin / metabolism*
  • Adiponectin / pharmacology*
  • Adipose Tissue / metabolism
  • Biomarkers
  • Brain / drug effects
  • Central Nervous System / drug effects*
  • Cognitive Dysfunction / metabolism*
  • Dementia / metabolism*
  • Estrogens / adverse effects
  • Female
  • Humans
  • Inflammation
  • Insulin
  • Insulin Resistance / physiology
  • Male
  • Memory / drug effects
  • Menopause / physiology
  • Obesity
  • PPAR alpha
  • Receptors, Adiponectin / metabolism
  • Risk Factors
  • Signal Transduction
  • Speech Disorders

Substances

  • ADIPOQ protein, human
  • ADIPOR1 protein, human
  • ADIPOR2 protein, human
  • Adiponectin
  • Biomarkers
  • Estrogens
  • Insulin
  • PPAR alpha
  • Receptors, Adiponectin
  • AMP-Activated Protein Kinases